Major Depressive Disorder

Latest News

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.
The Week in Review: April 8-12

April 13th 2024

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.
The Week in Review: April 1-5

April 6th 2024

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”
First Patient Dosed in Phase 2 Clinical Trial of NBI-1070770 for MDD

April 3rd 2024

MDD
ALTO-203 for Major Depressive Disorder and Anhedonia: Phase 2 Study Initiated

April 3rd 2024

digital therapeutic
Rejoyn Becomes First Prescription Digital Therapeutic Authorized for Treatment of MDD

April 1st 2024

Latest CME Events & Activities

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

More News

© 2024 MJH Life Sciences

All rights reserved.